No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

about

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

Item

http://www.wikidata.org/entity/Q54315498

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

@en

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

@nl

type

Item

label

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

@en

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

@nl

prefLabel

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

@en

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.

@nl

P1476

No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo

@en

P2093

Karoline Koch

http://www.w3.org/2001/XMLSchema#string

Monika Szczepanowski

http://www.w3.org/2001/XMLSchema#string

Niklas Vogt

http://www.w3.org/2001/XMLSchema#string

Wolfram Klapper

http://www.w3.org/2001/XMLSchema#string

P2860

Control of apoptosis and mitotic spindle checkpoint by survivin

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Cyclin D1 is a nuclear protein required for cell cycle progression in G1

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes.

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

P304

2134-2140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2014.975700

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Neus Masqué-Soler

Dimitry Abramov

P577

2014-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266945296

http://www.w3.org/2001/XMLSchema#string

P698

25315075

http://www.w3.org/2001/XMLSchema#string